CLINICAL STUDIES ON CEFUROXIME AXETIL (CXM-AX) IN RESPIRATORY TRACT INFECTIONS

Cefuroxime axetil (CXM-AX), a new oral cephem, was administered to 19 patients with respiratory tract infections, at the 250 mg-500 mg dose twice or three times a day for 3-14 days. And the clinical efficacy and safety were evaluated in 18 patients (2 acute bronchitis, 2 pneumonia, 8 chronic bronchi...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 34; no. Supplement5; pp. 584 - 588
Main Authors NIKI, YOSHIHITO, SUMI, MASARU, NAKAGAWA, YOSHIHISA, HINO, JIRO, KAWANISHI, MASAYOSHI, SOEJIMA, RINZO
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1986
Online AccessGet full text

Cover

More Information
Summary:Cefuroxime axetil (CXM-AX), a new oral cephem, was administered to 19 patients with respiratory tract infections, at the 250 mg-500 mg dose twice or three times a day for 3-14 days. And the clinical efficacy and safety were evaluated in 18 patients (2 acute bronchitis, 2 pneumonia, 8 chronic bronchitis, 2 pulmonary emphysema and 1 each of asthma with infection, diffuse panbronchiolitis, bronchiectasis and middle lobe syndrome). Clinical efficacy was “good” in 15 and “fair” in 3, and the efficacy rate was 83.3%. As a side effect, heartburn was observed in one case. In 4 cases, slight and transient eosinophilia, in one case leukocytopenia and in 2 cases slight elevation of GOT were observed.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.34.Supplement5_584